Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Alfred_W._Sandrock_Jr.
|
| gptkbp:collaboratesWith |
gptkb:Pfizer
gptkb:Novartis gptkb:Neurocrine_Biosciences |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
AAV gene therapy platforms
|
| gptkbp:focusesOn |
gptkb:Parkinson's_disease
gptkb:ALS gptkb:Huntington's_disease gene therapy neurological diseases |
| gptkbp:foundedYear |
2013
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Voyager Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:VY-AADC
TRACER AAV capsid discovery platform |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:VYGR
|
| gptkbp:website |
https://www.voyagertherapeutics.com/
|
| gptkbp:bfsParent |
gptkb:Third_Rock_Ventures
|
| gptkbp:bfsLayer |
6
|